Full metadata record
DC FieldValueLanguage
dc.creatorBoudet, F. (Florence)-
dc.creatorLasarte, J.J. (Juan José)-
dc.creatorSarobe, P. (Pablo)-
dc.creatorBorras-Cuesta, F. (Francisco)-
dc.creatorTheze, J. (Jacques)-
dc.date.accessioned2012-04-04T07:19:54Z-
dc.date.available2012-04-04T07:19:54Z-
dc.date.issued1996-
dc.identifier.citationBoudet F, Lasarte JJ, Sarobe P, Borras-Cuesta F, Theze J. Fine analysis of immunoreactivity of V3 peptides: antibodies specific for V3 domain of laboratory HIV type 1 strains recognize multiple V3 sequences synthesized from field HIV type 1 isolates. AIDS Res Hum Retroviruses 1996 Dec 10;12(18):1671-1679.es_ES
dc.identifier.issn1931-8405-
dc.identifier.urihttp://hdl.handle.net/10171/21583-
dc.description.abstractProduction of cross-reactive antibodies recognizing the V3 loop--that is, the principal neutralizing determinant (PND)--of various HIV-1 isolates is an important challenge in the development of passive immunotherapy or vaccinations against AIDS. We have produced two types of antibodies to the V3 domain of HIV-1: (1) antibodies against the HIV-1 MN laboratory strain generated in rabbits and (2) antibodies targeted to the HIV-1 LAI laboratory strain induced in chimpanzees. These antibodies were shown to be specific for HIV-1 subtype B. The cross-reactivity of these antibodies has been evaluated against a large panel of peptides representing different parts of the V3 loop. Seventy-five peptides, referred to as clinical peptides, were synthesized according to HIV-1 sequences recovered from PMBCs of 27 patients followed in three Parisian hospitals. Thirteen V3 peptides derived from 4 HIV-1 laboratory strains (MN, LAI, SF2, and RF) were also included in the study. The results show that both the amino-terminal and central parts of the V3 loop are immunogenic. The rabbit antibodies against the amino-terminal end of the PND proved to be highly cross-reactive against the clinical peptides. The anti-gp160 antibodies induced in one chimpanzee recognized a significant proportion of the panel of V3 clinical sequences. These antibodies cross-reacted mainly with the apex of the V3 loop. These data give some additional indications on the immunogenicity of the V3 loop and further demonstrate that extensive cross-reactivity of anti-V3 antibodies can be obtained on field HIV-1 isolates despite the high variability of the V3 loop amino acid sequence.es_ES
dc.language.isoenges_ES
dc.publisherMary Ann Liebertes_ES
dc.rightsinfo:eu-repo/semantics/closedAccess-
dc.subjectHIV Antibodies/immunologyes_ES
dc.subjectHIV Envelope Protein gp120/immunologyes_ES
dc.subjectHIV Envelope Protein gp160/immunologyes_ES
dc.subjectHIV Infections/virologyes_ES
dc.subjectHIV-1/immunologyes_ES
dc.subjectPeptide Fragments/immunologyes_ES
dc.titleFine analysis of immunoreactivity of V3 peptides: antibodies specific for V3 domain of laboratory HIV type 1 strains recognize multiple V3 sequences synthesized from field HIV type 1 isolateses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttp://online.liebertpub.com/doi/abs/10.1089/aid.1996.12.1671?2es_ES
dc.type.driverinfo:eu-repo/semantics/articlees_ES

Files in This Item:
There are no files associated with this item.


Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.